Innovative use of intravesical tacrolimus for hemorrhagic radiation cystitis.

Abstract

Hemorrhagic cystitis is a rare and severe late complication of pelvic radiation, and there is no regulatory-approved drug treatment. We present an 81-year-old man with a history of localized prostate cancer, which was treated with external beam radiation therapy and subsequently developed severe hemorrhagic radiation cystitis for which he has failed several treatments. We present the novel use of intravesical tacrolimus for the treatment of refractory radiation cystitis and gross hematuria. The patient tolerated the treatment well, and it resulted in the resolution of his gross hematuria without further consideration for formalin instillation or cystectomy and diversion. Intravesical tacrolimus is a safe, minimally invasive, and promising treatment option for radiation hemorrhagic cystitis.

• Authors: Chirag N Dave, Fahad Chaus, Michael B Chancellor, Michelle Lajness, Kenneth M Peters
• Journal: International urology and nephrology (Int Urol Nephrol) Vol. 47 Issue 10 Pg. 1679-81 (Oct 2015) ISSN: 1573-2584 [Electronic] Netherlands
• PMID: 26347076 (Publication Type: Case Reports, Journal Article)

Chemical References

• Calcineurin Inhibitors
• Tacrolimus

Topics

• Administration, Intravesical
• Aged, 80 and over
• Calcineurin Inhibitors (administration & dosage)
• Cystitis (drug therapy, etiology)
• Hematuria (drug therapy, etiology)
• Humans
• Male
• Prostatic Neoplasms (radiotherapy)
• Radiation Injuries (drug therapy, etiology)
• Radiotherapy (adverse effects)
• Tacrolimus (administration & dosage)